The In Situ Hybridization Market accounted to USD 550.0 million in 2016 growing at a CAGR of 5.4% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ) or if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs). This is distinct from immunohistochemistry, which usually localizes proteins in tissue sections.
The In situ Hybridization is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells which helps in obtaining spatial information about gene expression.
Chief Market Drivers and Restraints:
- Increasing prevalence of cancer disease
- Increasing diagnosis of cancer disease
- Advancement in therapeutics technology
- Rising government initiatives
- Increasing demand of accurate prognostic tools
- Increasing healthcare expenditure
Get Exclusive Free Sample Report at: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-in-situ-hybridization-market
Competitive Analysis: Global In Situ Hybridization Market
In situ Hybridization market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of In situ Hybridization market for global, Europe, North America, Asia Pacific and South America.
Major Market Competitors: Global In Situ Hybridization Market
Some of the major players operating in In situ Hybridization market are
- Medtronic (Ireland)
- General Electric Company
- Siemens AG
- Brainlab AG
- Koninklijke Philips NV
- IMRIS Deerfield Imaging
- NeuroLogica Corporation
- Ziehm Imaging GmbH
- Toshiba Corporation
- Shimadzu Corporation
- Neurologica Corporation
- Imris Inc. among others.
Know More Business Opportunities in situ Hybridization market. Speak To Our Analyst And Gain Crucial Industry Insights That Will Help Your Business Expand. Request Analyst Call for More Insight https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-in-situ-hybridization-market
Market Segmentation: Situ Hybridization Market
By product type the In situ Hybridization market is segmented into Flurocent In-Situ Hybridization (FISH) and Chromogenic In-Situ Hybridization (CISH). Flurocent In-Situ Hybridization is further segmented into DNA – FISH and RNA – FISH. Chromogenic In-Situ Hybridization is further segmented into DNA – CISH and RNA – CISH.
By application the market is segmented into cell biology research, neuroscience, oncology, others.
On the basis of end user the market is segmented into pharma and biotechnology laboratories, research and academics, hospitals and others.
On the basis of geography, In situ Hybridization market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major companies covered in this report are Agilent Technologies, Thermo Fisher Technologies, Affymetrix, Abbot Laboratories, Vector Laboratories, Inc., Advanced Cell Diagnostics, Nordic BioSite AB, Abcam Plc, Genemed Biotechnologies, Inc., Sigma-Aldrich Co. LLC, BioVisible BV, PerkinElmer Inc., Abnova Corporation, Enzo Life Sciences Inc., Bio SB, Elchrom Scientific AG among other companies.
…And More GET DETAILED TOC AT: https://databridgemarketresearch.com/toc/?dbmr=global-in-situ-hybridization-market